Enliven Therapeutics, Inc. (ELVN)
(Delayed Data from NSDQ)
$21.88 USD
-0.34 (-1.53%)
Updated Aug 30, 2024 03:59 PM ET
After-Market: $21.88 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth C Momentum D VGM
Balance Sheet
Fiscal Year End for Enliven Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 253 | 88 | 90 | 88 | 29 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 13 | 1 | 2 | 2 | 2 |
Total Current Assets | 266 | 90 | 93 | 90 | 31 |
Net Property & Equipment | 1 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 1 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 4 | 2 | 0 | 0 | 2 |
Total Assets | 272 | 92 | 94 | 91 | 33 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 0 | 2 | 2 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 15 | 2 | 5 | 4 | 3 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 10 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 26 | 2 | 7 | 6 | 4 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 26 | 2 | 8 | 6 | 4 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 78 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 400 | 236 | 234 | 181 | 6 |
Retained Earnings | -154 | -146 | -148 | -96 | -55 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 246 | 90 | 86 | 84 | 29 |
Total Liabilities & Shareholder's Equity | 272 | 92 | 94 | 91 | 33 |
Total Common Equity | 246 | 90 | 86 | 84 | -49 |
Shares Outstanding | 41.20 | 6.50 | 6.50 | 4.30 | NA |
Book Value Per Share | 5.97 | 13.87 | 13.24 | 19.64 | 0.00 |
Fiscal Year End for Enliven Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 312 | 321 | 253 | 263 | 278 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 17 | 13 | 5 | 5 |
Total Current Assets | 318 | 337 | 266 | 269 | 283 |
Net Property & Equipment | 1 | 1 | 1 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 1 | 1 | 1 | 1 | 1 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 8 | 4 | 4 | 4 | 3 |
Total Assets | 327 | 343 | 272 | 274 | 289 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 3 | 1 | 1 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 12 | 12 | 15 | 11 | 6 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 9 | 10 | 10 | 0 | 0 |
Total Current Liabilities | 22 | 25 | 26 | 12 | 9 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 22 | 25 | 26 | 12 | 10 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 502 | 495 | 400 | 397 | 393 |
Retained Earnings | -197 | -177 | -154 | -135 | -114 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 305 | 318 | 246 | 262 | 279 |
Total Liabilities & Shareholder's Equity | 327 | 343 | 272 | 274 | 289 |
Total Common Equity | 305 | 318 | 246 | 262 | 279 |
Shares Outstanding | 47.00 | 47.00 | 41.20 | 41.20 | 41.10 |
Book Value Per Share | 6.49 | 6.76 | 5.97 | 6.35 | 6.79 |